Development of a Prediction Score for the Occurrence of Death or Lung Transplantation in Patients With Emphysema Secondary to Alpha-1-anti-tripsin Deficiency (FLARE)
Emphysema linked to alpha-1-antitrypsin deficiency (DAAT): towards a better prediction of risks Emphysema caused by alpha-1-antitrypsin deficiency (DAAT) is a rare genetic disorder that can lead to serious complications, such as the need for a lung transplant or death, affecting up to 15% of patients. The only specific treatment available is a weekly infusion of alpha-1-antitrypsin (IV-AAT), an expensive and burdensome therapy.
Currently, there is no reliable model to predict the course of the disease in these patients. Our study, conducted in several French hospitals, aims to develop a prediction tool combining clinical, biological, functional data and advanced medical image analysis (lung CT). This model will make it possible to identify the most at-risk patients, in order to better adapt their care, anticipate transplant needs and avoid unnecessary treatments for low-risk patients.
Ultimately, this approach could also improve access to care for patients who need it most, while optimizing health system resources.
Visão geral do estudo
Status
Descrição detalhada
Context. Emphysema secondary to alpha-1-anti-trypsin deficiency (AATD) is a genetic rare disease, but with pejorative events such as death or lung transplantation (LT) which affect up to 15% of patients. Aside from standard medical care for COPD management, the only specific treatment as augmentation therapy for severe AATD, is weekly intravenous alpha-1 antitrypsin (IV-AAT) which is still expensive and restrictive. Several prognostic scores for tobacco-related COPD have been developed but, none of them have been validated in AATD, neither have included quantitative chest CT imaging while they have been associated with mortality in emphysema. Therefore, we aim to develop a prediction model combining clinical, biological, functional and quantitative CT data (including radiomics) for mortality or LT to identify at-risk patients with emphysema secondary to AATD.
Methods: From several French hospitals, we'll conduct a multicenter retrospective study based on data collected in usual care among patients over 18-year-old, with an available chest CT. We'll collect clinical data (BMI, mMRC dyspnea scale), respiratory function parameters and quantitative imaging data (including radiomics) from the initial CT from AATD patients secondary to ZZ, Znull, ZMalton, Z and rare mutations. We'll then validate our results on an independent external database from the European AADT cohort (EARCO), with specific dedicated funding.
Perspectives: To develop a prediction model to identify the AATD patients at risk of clinical deterioration, defined by death or LT allowing for personalized care, in order to: 1. anticipate registration on the transplant list, 2. optimize overall management, including pharmacological (IV-AAT) and non-pharmacological management. 3. to avoid cost-prohibitive and constraining IV-AAT infusion for low risk patients For Health policy, finding a way to target high-risk patients may help a better access for IV-AAT to appropriate individuals.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Maéva ZYSMAN, MD, PhD
- Número de telefone: +335 57 65 63 38
- E-mail: maeva.zysma@chu-bordeaux.fr
Estude backup de contato
- Nome: Margot GENAUD
- Número de telefone: +335 25 35 21 94
- E-mail: margot.genaud@chu-bordeaux.fr
Locais de estudo
-
-
-
Bron, França, 69677
- Recrutamento
- Hospices Civils de Lyon
-
Contato:
- Jean-Francois MORNEX, MD, PhD
- Número de telefone: +334 72 11 80 17
- E-mail: jean-francois.mornex@univ-lyon1.fr
-
Investigador principal:
- Jean-Francois MORNEX, MD, PhD
-
Lille, França, 59000
- Recrutamento
- CHU de Lille
-
Contato:
- Olivier LE ROUZIC, MD, PhD
- Número de telefone: +333 20 16 05 30
- E-mail: Olivier.LEROUZIC@chu-lille.fr
-
Investigador principal:
- Olivier LE ROUZIC, MD, PhD
-
Paris, França, 75018
- Recrutamento
- Hopital Bichat Claude-Bernard
-
Contato:
- Vincent BUNEL GOURDY, MD
- Número de telefone: +331 40 25 61 01
- E-mail: vincent.bunel@aphp.fr
-
Investigador principal:
- Vincent BUNEL GOURDY, MD
-
Pessac, França, 33600
- Recrutamento
- Bordeaux University Hospital
-
Contato:
- Maéva ZYSMAN, MD, PhD
- Número de telefone: +335 57 65 63 38
- E-mail: maeva.zysma@chu-bordeaux.fr
-
Contato:
- Margot GENAUD
- Número de telefone: +335 25 35 21 94
- E-mail: margot.genaud@chu-bordeaux.fr
-
Investigador principal:
- Maéva ZYSMAN, MD,PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion criteria:
- diagnosed between 2010 and 2025
- in the pulmonology department
- diagnosis of emphysema and COPD secondary to alpha-1 antitrypsin deficiency ZZ, Znull, ZMalton, Z and rare mutations,
- emphysema according to the initial thoracic CT scan (+/- 12 months after diagnosis).
Exclusion criteria:
- Age <18 years
- Patient opposed to the use of their data for research purposes
- Patient deprived of liberty by judicial decision
- Patient not affiliated with a social security scheme
- no CT scan available
- no lung function test available the year around CT scan
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Emphysema secondary to alpha-1-anti-trypsin deficiency (AATD)
The subjects included will be any patients followed and diagnosed between 2010 and 2025 in the pulmonology department for emphysema and COPD secondary to alpha-1 antitrypsin deficiency ZZ, Znull, ZMalton, Z and rare mutations, based on the diagnosis of emphysema made from an initial thoracic CT scan (+/- 12 months after diagnosis).
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Evaluation of vital status
Prazo: 5 years
|
Death within 5 years of emphysema diagnosis.
|
5 years
|
|
Evaluation of transplantation status
Prazo: 5 years
|
Lung transplantation within 5 years of emphysema diagnosis.
|
5 years
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PA, Thompson PJ, Hernandez P, Chlumsky J, Teschler H, Ficker JH, Seersholm N, Altraja A, Makitaro R, Chorostowska-Wynimko J, Sanak M, Stoicescu PI, Piitulainen E, Vit O, Wencker M, Tortorici MA, Fries M, Edelman JM, Chapman KR; RAPID Extension Trial Group. Long-term efficacy and safety of alpha1 proteinase inhibitor treatment for emphysema caused by severe alpha1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017 Jan;5(1):51-60. doi: 10.1016/S2213-2600(16)30430-1. Epub 2016 Dec 2.
- Ho ESY, Ellis PR, Kavanagh D, Subramanian D, Stockley RA, Turner AM. Proposal and Validation of the Minimum Clinically Important Difference in Emphysema Progression. Chronic Obstr Pulm Dis. 2025 Mar 27;12(2):109-116. doi: 10.15326/jcopdf.2024.0511.
- Stolk J, Stockley RA, Piitulainen E, Stoel BC. Relationship between Change in Lung Density and Long-Term Progression of Lung Function. Am J Respir Crit Care Med. 2015 Jul 1;192(1):114-6. doi: 10.1164/rccm.201502-0370LE. No abstract available.
- Sieluk J, Levy J, Sandhaus RA, Silverman H, Holm KE, Mullins CD. Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States. Chronic Obstr Pulm Dis. 2018 Nov 8;6(1):6-16. doi: 10.15326/jcopdf.6.1.2017.0187.
- Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2003 May 15;167(10):1387-92. doi: 10.1164/rccm.200209-1035OC. Epub 2003 Feb 5.
- Fraughen DD, Ghosh AJ, Hobbs BD, Funk GC, Meischl T, Clarenbach CF, Sievi NA, Schmid-Scherzer K, McElvaney OJ, Murphy MP, Roche AD, Clarke L, Strand M, Vafai-Tabrizi F, Kelly G, Gunaratnam C, Carroll TP, McElvaney NG. Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis. Am J Respir Crit Care Med. 2023 Nov 1;208(9):964-974. doi: 10.1164/rccm.202305-0863OC.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doenças Genéticas, Congênitas
- Doenças Respiratórias
- Doenças do aparelho digestivo
- Doenças pulmonares
- Doenças do Fígado
- Enfisema subcutâneo
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Enfisema
- Deficiência de alfa 1-antitripsina
Outros números de identificação do estudo
- CHUBX 2024/85
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .